Drugs

PEER-REVIEWED FEATURE

Daridorexant: Adis Evaluation

Key Points

- A dual orexin receptor antagonist is being developed by Idorsia Pharmaceuticals Ltd. for the treatment of insomnia
- Received its first approval on January 7 2022 in the USA
- Approved for use in adult patients with insomnia characterized by difficulties with sleep onset and/or sleep maintenance

Summary

Daridorexant (Quviviq™; Idorsia Pharmaceuticals Ltd.) is an orally administered dual orexin type 1 and type 2 (OX1 and OX2) receptor antagonist (DORA) being developed for the treatment of insomnia. It was selected from a pool of drug candidates on the basis of an expected effect duration of ≈ 8 hours at a dose of 25 mg, with a half-life intended to minimize residual effects that might impair daytime functioning. Based on the results of two pivotal phase III trials, daridorexant was recently approved in the USA for the treatment of adult patients with insomnia characterized by difficulties with sleep onset and/or sleep maintenance. This article summarizes the milestones in the development of daridorexant leading to this first approval.

Markham, A. Drugs. 2022. https://doi.org/10.1007/s40265-022-01699-y